Characteristics and clinical outcomes after doxycycline treatment in otosyphilis
| No. | Age (years) | Gender | Side | Duration (years) | CSF WBC count (cell/mm3) | CSF protein (mg/dl) | Clinical response | Audiogram response | Serum VDRL | |
| Pre-treatment | Post-treatment | |||||||||
| 1 | 66 | m | b | 1 | 0 | 130 | No change | No change | 1:4 | 1:2 |
| 2 | 65 | m | b | <1 | 2 | 22 | No change | No change | 1:8 | 1:4 |
| 3 | 70 | f | b | <1 | 2 | 24 | No change | Worse | 1:2 | 1:4 |
| 4 | 74 | m | b | <1 | 1 | 122 | Improved | Improved | 1:1 | NA |
| 5 | 63 | m | u | <1 | 0 | 32 | Improved | Improved | NR | NR |
| 6 | 61 | f | b | 3 | 4 | 35 | No change | Improved | 1:4 | 1:4 |
| 7 | 60 | m | b | 5 | 0 | 42 | Improved | Improved | 1:2 | NR |
| 8 | 66 | m | b | <1 | 0 | 99 | No change | Worse | 1:1 | 1:1 |
| 9 | 70 | f | b | <1 | 4 | 57 | Improved | Improved | 1:4 | 1:1 |
| 10 | 82 | m | b | <1 | 1 | 33 | No change | No change | 1:2 | NA |
| 11 | 63 | f | b | 10 | 4 | 99 | No change | Improved | 1:4 | NA |
| 12 | 67 | m | b | 10 | 2 | 18 | No change | No change | 1:2 | 1:2 |
| 13 | 54 | f | u | 1 | 0 | 26 | Improved | Worse | NR | NR |
| 14 | 79 | m | b | 2 | 2 | 26 | Improved | Worse | 1:2 | NA |
| 15 | 69 | f | b | 10 | 4 | 18 | No change | Improved | 1:4 | NA |
| 16 | 74 | m | b | 3 | 0 | 56 | No change | No change | NR | NR |
| 17 | 84 | m | b | 1 | 2 | 51 | Improved | No change | 1:2 | 1:2 |
| 18 | 75 | m | b | <1 | 0 | 52 | Improved | No change | NR | NR |
| 19 | 70 | f | b | <1 | 1 | 22 | Improved | No change | 1:1 | NR |
All patients had non-reactive CSF VDRL.
m, male; f, female; Side, side of hearing loss; b, bilateral; CSF, cerebrospinal fluid; WBC, white blood cell; VDRL, the Veneral Disease Research Laboratory Test; post-treatment serum VDRL at 1 year-follow up; NR, non-reactive; NA, not applicable.